- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/575 - Hormones
Patent holdings for IPC class C07K 14/575
Total number of patents in this class: 1583
10-year publication summary
|
134
|
118
|
128
|
119
|
115
|
111
|
82
|
100
|
114
|
75
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novo Nordisk A/S | 2285 |
59 |
| Eli Lilly and Company | 4101 |
34 |
| Sanofi | 4320 |
31 |
| Zealand Pharma A/S | 269 |
28 |
| Protagonist Therapeutics, Inc. | 154 |
25 |
| Janssen Pharmaceutica N.V. | 3161 |
23 |
| Hanmi Science Co., Ltd. | 135 |
18 |
| The General Hospital Corporation | 4869 |
17 |
| The Regents of the University of California | 20802 |
16 |
| H. Lundbeck A/S | 1235 |
16 |
| Ip2ipo Innovations Limited | 171 |
16 |
| Dana-Farber Cancer Institute, Inc. | 2668 |
15 |
| I2o Therapeutics, Inc. | 32 |
15 |
| Hanmi Pharm. Co., Ltd. | 604 |
14 |
| Boehringer Ingelheim International GmbH | 4483 |
13 |
| University of Florida Research Foundation, Inc. | 4184 |
13 |
| University of Miyazaki | 131 |
13 |
| Centre National de La Recherche Scientifique | 11055 |
12 |
| Amgen Inc. | 4436 |
12 |
| President and Fellows of Harvard College | 6104 |
11 |
| Other owners | 1182 |